N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 2 ClinicalTrials.gov

Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Sponsor: Hefei Cancer Hospital of the Chinese Academy of Sciences • ClinicalTrials.gov ID: NCT07787273

Registry updated: 2026-08-26
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Based on previous mechanistic research and preliminary clinical data, this trial intends to generate high-level evidence for this therapeutic strategy, which may improve the treatment landscape for patients with locally advanced esophageal squamous cell carcinoma.

Interventions

  • Interferon-γ (Drug)
    1,000,000 IU administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.
  • Camrelizumab (Drug)
    200 mg administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.

Eligibility criteria

Inclusion Criteria: 1. Aged \>= 18 years; 2. Histologically confirmed esophageal squamous cell carcinoma (ESCC), clinical stage cT1b-3, N+, M0; 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 4. Expected overall survival \> 6 months; 5. Adequate bone marrow, hepatic, renal, coagulation, and thyroid function. Exclusion Criteria: 1. Active autoimmune disease; 2. Requirement for systemic immunosuppressive therapy; 3. Hypersensitivity to any study drug; 4. Uncontrolled significant organ disease (e.g., cardiac, pulmonary, hepatic, renal) or active infection; 5. Pregnant or lactating female.

Conditions

Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant Therapy Camrelizumab

Locations

  • Hefei Cancer Hospital, Chinese Academy of Sciences — Hefei, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University — Hefei, Anhui, China
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record